|
|
´ëÇѳ»°úÇÐȸÁö : Á¦ 73 ±Ç Á¦ 3 È£ 2007 - 299 - º£Æ®³² ÂüÀü °í¿±Á¦ ȯÀÚ¿¡¼ ½ÉÇ÷°ü ÁúȯÀÇ ¹ß»ýÀÌ ´õ ÈçÇÑ°¡? ±¤ÁÖº¸Èƺ´¿ø ¼øȯ±â³»°ú, Àü³²´ëÇб³º´¿ø ½ÉÀå¼¾ÅÍ2 °¿øÀ¯․±èÇѱÕ․Á¤¸íÈ£2․Á¶»óö․Á¤¾È´ö Á¶¿ëÂù․±â¿µÈ․À̺À±Ô․Ȳ¼±È£․±è ¿ø․±è ¿Ï =Abstract= Is cardiovascular disease more common in Vietnam veterans exposed to agent orange? Won Yu Kang, M.D., Han Gyun Kim, M.D., Myung Ho Jeong, M.D.2, Sang Cheol Cho, M.D., An Doc Jung, M.D., Yong Chan Cho, M.D., Young Hwa Ki, M.D., Bong Gyu Lee, M.D., Sun Ho Hwang, M.D., Weon Kim, M.D., PhD. and Wan Kim, M.D. Division of Cardiology, Department of Internal Medicine, Gwangju Veterans Hospital, Gwangju, Korea The Heart Center of Chonnam National University Hospital2, Gwangju, Korea Background : TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin), a material of agent orange, was reported as a deadly poison in spite of its presence at extremely small doses. It has been reported that TCDD can cause various kinds of cancers and harmful effects on humans. However, a correlation between exposure to TCDD and cardiovascular disease is not yet known. Thus, we intended to examine the correlation between TCDD exposure and cardiovascular disease through an analysis of coronary angiograms in veterans of the Vietnam War. Methods : A consecutive 115 patients undergoing coronary angiograms between April 2004 and June 2005 at Gwangju Veterans Hospital were analyzed. The patients were divided into two groups: 57 patients exposed to TCDD (Group I, average age 59.2¡¾4.2 years) and 58 patients that were not exposed to TCDD (Group II, Average age 60.1¡¾5.6 years). The clinical and coronary angiographic findings were evaluated. Results : Baseline clinical characteristics, inflammatory markers and echocardiographic parameters were not different between patients in the two groups. The incidence of diabetes (43.9% vs. 25.0%, p=0.035) and hyperlipidemia (47.4% vs. 27.6%, p=0.028) were higher in group I patients than group II patients. Significant coronary artery stenosis was more common in group I (45 cases, 78.9%) thanin group II (33 cases, 56.9%) (p=0.011). Conclusions : There was a higher incidence of diabetes, hyperlipidemia, and significant coronary artery stenosis in patients that underwent a diagnostic coronary angiogram that were previously exposed to TCDD.(Korean J Med 73:299-306, 2007) Key Words : Drugs, Coronary diseases, Angioplasty ∙Received : 2006. 7. 7 ∙Accepted : 2006. 8. 28 ∙Correspondence to : Han Gyun Kim, M.D., Division of cardiology, Department of Internal Medicine, Gwangju Veterans Hospital, 887-1 Sanwol-dong, Gwangsan-gu, Gwangju 506-705, Korea E-mail : onebac@nate.com *This research was performed under support of the cardiovascular research foundation(CVRF), and we showed the oral presentation in the 56th annual scientific meeting of the Korean association of internal medicine held on October 27-28, 2005. £ The Korean Journal of Medicine : Vol. 73, No. 3, 2007 £ - 300 - ¼ ·Ð °í¿±Á¦(Agent orange)´Â º£Æ®³² ÀüÀï ´ç½Ã ¹Ì±ºÀÌ Àû ±ºÀÇ Àº½Åó³ª ¾Æ±ºÀÇ ½Ã°èû¼Ò¸¦ À§ÇØ »ç¿ëÇÑ ¹°Áú·Î, ±× Áß dioxinÀ¸·Î Àß ¾Ë·ÁÁø TCDD (2,3,7,8-tetrachlorodibenzo- p-dioxin)´Â ¹Ì·® Æ÷ÇԵǾî ÀÖÀ¸³ª, ¼Ò·® À¸·Îµµ ÀÎü¿¡ ¸Íµ¶¼ºÀÌ ÀÖ´Â °ÍÀ¸·Î º¸°íµÇ¾î ÀÖ´Ù1, 2). DioxinÀÌ ÀÏ´Ü Ã¼³»·Î µé¾î¿Ã °æ¿ì¿¡ ü¿Ü·Î ¹è¼³ÀÌ µÇ Áö ¾Ê°í ü³»¿¡ ÃàÀûµÊÀ¸·Î½á, Àå±âÀûÀ¸·Î ÇÕº´ÁõÀ» ¹ß »ý½ÃŲ´Ù3, 4). ÇÏÁö¸¸ °í¿±Á¦¿Í ÀÌ·Î ÀÎÇÑ ÈÄÀ¯Áõ¿¡ ´ëÇÑ ¸íÈ®ÇÑ ÀÎ °ú°ü°è°¡ ¹àÇôÁ® ÀÖ´Â °ÍÀÌ ¸¹Áö ¾ÊÀ¸¸ç, ƯÈ÷ °íÇ÷¾Ð, °íÁöÇ÷Áõ, µ¿¸Æ°æÈÁõ, ±×¸®°í ÇãÇ÷¼º ½ÉÁúȯÀÇ ¹ß»ý°ú °í¿±Á¦ÀÇ Àΰú°ü°è´Â ºÒºÐ¸íÇÑ »óÅÂÀÌ´Ù. ÀúÀÚ µîÀº º£Æ®³² ÀüÀï¿¡ Æĺ´µÇ¾ú´ø ȯÀÚµéÀ» ´ë»ó À¸·Î ÇÏ¿© °í¿±Á¦°¡ ½ÉÇ÷°üÁúȯÀÇ ¹ßº´¿¡ ¾î¶°ÇÑ ¿µÇâ À» ¹ÌÄ¡´ÂÁö¿Í °í¿±Á¦¿¡ Æø·ÎµÇ¾ú´ø »ç¶÷µéÀÇ ½ÉÇ÷°ü ÁúȯÀÇ Æ¯Â¡À» ¾Ë¾Æº¸°íÀÚ ÇÏ¿´´Ù. ´ë»ó ¹× ¹æ¹ý 1. ´ë»ó ȯÀÚ 2004³â 4¿ùºÎÅÍ 2005³â 6¿ù±îÁö ±¤ÁÖº¸Èƺ´¿ø¿¡¼ Çù ½ÉÁõÀ¸·Î °ü»óµ¿¸Æ Á¶¿µ¼úÀ» ½ÃÇàÇÑ È¯ÀÚµéÀ» ´ë»óÀ¸·Î ÇÏ¿´´Ù. ³ªÀÌ´Â º£Æ®³² ÀüÀï´ç½Ã Çѱ¹±º Æĺ´ ±â°£À» °í ·ÁÇÏ¿© 50 ³»Áö 70¼¼ÀÇ ³²ÀÚ È¯ÀÚ·Î Á¦ÇÑÇÏ¿´´Ù. °í¿±Á¦ ¿¡ ³ëÃâµÈ ȯÀÚ¸¦ I±º(57¸í), ³ëÃâµÇÁö ¾ÊÀº ȯÀÚ, Áï º£ Æ®³² ÀüÀï¿¡ Æĺ´µÇÁö ¾Ê¾ÒÀ¸¸ç ±âŸ °í¿±Á¦ ³ëÃâµÉ À§ Ç輺ÀÌ ÀÖ´Â Á÷¾÷·Â µîÀÌ ¾ø´Â ȯÀÚ¸¦ II±º(58¸í)À¸·Î ºÐ ·ùÇÏ¿© ºñ±³ ºÐ¼®ÇÏ¿´´Ù. 2. ¹æ¹ý ´ë»ó ȯÀÚ´Â ³»¿ø ½Ã ÀÛ¼ºµÈ Àǹ«±â·ÏÁö ¹× °ü»óµ¿¸Æ Á¶¿µ¼ú ¼Ò°ßÀ» Åä´ë·Î ÇÏ¿© ÈÄÇâÀûÀ¸·Î ºÐ¼®ÇÏ¿´´Ù. ȯ ÀÚÀÇ ³ªÀÌ, üÁú·®Áö¼ö(body mass index: BMI), °ü»óµ¿ ¸Æ ÁúȯÀÇ À§ÇèÀÎÀÚ(°íÇ÷¾Ð, ´ç´¢º´, °íÁöÇ÷Áõ, Èí¿¬), ¹ß ¸ñ»ó¿ÏÁö¼ö/¸ÆÆÄÀüÆļӵµ(Ankle brachial index/Pulse wave velocity: ABI/PWV), Framingham risk score5), °Ë»ç½Ç ¼Ò°ß, ½ÉÃÊÀ½Æĵµ¿¡¼ ÁÂ½É½Ç ±¸Ç÷À² µîÀ» Á¶»ç ÇÏ¿´´Ù. °ü»óµ¿¸Æ Á¶¿µ¼ú¿¡¼ ¼¼ Ç÷°ü Áß ÇÑ Ç÷°ü¿¡¼¶ó µµ 50% ÀÌ»óÀÇ ÇùÂøÀ» º¸ÀÌ´Â °æ¿ì º´º¯ÀÌ ÀÖ´Â °ÍÀ¸·Î Á¤ÀÇÇÏ¿´´Ù. °ü»óµ¿¸Æ Á¶¿µ¼úÀº GE INOVA 2000¢ç·Î ½ÃÇàÇÏ¿´À¸ ¸ç, Á¤·®Àû °ü»óµ¿¸Æ ºÐ¼®Àº Cardiology AI 1000¢çÀÇ ÇÁ ·Î±×·¥À» ÀÌ¿ëÇÏ¿© ÃøÁ¤ÇÏ¿´´Ù. ¼º°øÀûÀÎ °æÇÇÀû °ü»óµ¿ ¸Æ ÁßÀç¼ú(percutaneous coronary intervention: PCI)ÀÇ Á¤ÀÇ´Â »ç¸Á, ±Þ¼º ½É±Ù°æ»öÁõ, ±ä±Þ °æÇÇÀû Àç°ü·ù¼ú, ±ä±Þ ¿Ü°úÀû ¿ìȸ¼ú(coronary artery bypass graft: CABG) µî ÇÕº´Áõ ¾øÀÌ ÀÜ¿© ÇùÂøÀÌ 30% ¹Ì¸¸À̸ç, Thrombolysis In Myocardial Infarction (TIMI) Ç÷·ùµî±Þ III ÀÌ»óÀÎ °æ¿ì·Î Á¤ÀÇÇÏ¿´´Ù. º´º¯Ç÷°üÀÇ ¼ö¿Í °ü»óµ¿¸Æ ¿ÏÀüÆó¼â À¯¹«, TIMI flow µîÀ» ÃøÁ¤ÇÏ¿´À¸¸ç, PCI À¯¹« ¸¦ ±â·ÏÇÏ¿´´Ù. °ü»óµ¿¸Æ º´º¯ÀÇ ÇüÅÂÇÐÀû ºÐ·ù´Â ACC /AHA (American College of Cardiology/American Heart Association)¿¡¼ Á¦½ÃÇÑ ACC/AHA classificationÀ» Âü °íÇÏ¿´´Ù6). 3. Åë°è ºÐ¼® ÀÚ·á´Â Æò±Õ¡¾Ç¥ÁØÆíÂ÷·Î Ç¥½ÃÇÏ¿´°í, SPSS for windows (Version 12.0) Åë°è ¼ÒÇÁÆ®¿þ¾î¸¦ »ç¿ëÇÏ¿´À¸ ¸ç, ¸í¸ñÀÚ·á ¹× ¿¬¼ÓÀÚ·á´Â °¢°¢ Chi-square¿Í 2-tailed independent sample t-test·Î ºñ±³ ºÐ¼®ÇÏ¿´´Ù. ¸ðµç ÀÚ ·á´Â p °ªÀÌ 0.05 ¹Ì¸¸ÀÎ °æ¿ì¸¦ À¯ÀǼºÀÌ ÀÖ´Â °ÍÀ¸·Î ÆÇÁ¤ÇÏ¿´´Ù. °á °ú 1. ´ë»ó ȯÀÚÀÇ ÀÓ»óÀû Ư¡ Æò±Õ ¿¬·ÉÀº ¾ç ±º °£¿¡ Â÷ÀÌ´Â ¾ø¾úÀ¸¸ç, Çù½ÉÁõÀ̳ª ±Þ¼º ½É±Ù°æ»öÁõÀÇ °ú°Å·Âµµ ¾ç ±º °£ÀÇ Â÷ÀÌ´Â º¸ÀÌÁö ¾Ê¾Ò´Ù. °íÇ÷¾ÐÀÌ I±º¿¡¼ ´õ ³ôÀº À¯º´À²À» º¸¿´À¸³ª, Åë°èÀûÀÎ Àǹ̴ ¾ø¾ú´Ù. ÇÏÁö¸¸ I±º¿¡¼ ´ç´¢º´(Group I: 43.9%, Group II: 25.0%, p=0.035)°ú °íÁöÇ÷Áõ(I±º: 47.4%, II±º: 27.6%, p=0.028)ÀÌ À¯ÀÇÇÏ°Ô ³ô¾Ò´Ù. ±âŸ BMI³ª ABI/PWV, ÁÂ½É½Ç ±¸Ç÷À² µîÀº ¾ç ±º °£¿¡ Â÷ÀÌ ´Â ¾ø¾ú´Ù(Ç¥ 1). ¾ç ±º °£¿¡ ¿°Áõ Ç¥ÁöÀÚ³ª ½É±ÙÈ¿¼Ò ¼ö Ä¡, Ç÷Áß ÁöÁú ¼öÄ¡ µî¿¡¼µµ À¯ÀÇÇÑ Â÷ÀÌ´Â º¸ÀÌÁö ¾Ê ¾Ò´Ù(Ç¥ 2). I±º¿¡¼ °íÁöÇ÷ÁõÀÌ À¯ÀÇÇÏ°Ô ³ô¾ÒÀ½¿¡µµ Ç÷ Áß ÁöÁú ¼öÄ¡¿¡¼ ¾ç ±º »çÀÌ¿¡ Â÷ÀÌ´Â ¾ø¾ú´ø °ÍÀº I±º ¿¡¼ ÀÌ¹Ì ÁöÁú°ÇÏÁ¦ µîÀÇ Ä¡·á¸¦ ÇÏ¿´±â ¶§¹®ÀÌ´Ù. |
±¤ÁÖ¡¤Àü³² °í¿±Á¦ ÈÄÀ¯ÀÇÁõ È£¼Ò ÆÄ¿ù±ºÀÎ 4700¸í |
¿ùÂü Áß¾Óȸ °³Çõ |